Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman

Last updated: August 28, 2023
Sponsor: Rajavithi Hospital
Overall Status: Terminated

Phase

2/3

Condition

Vaginitis

Vaginal Atrophy

Treatment

Placebo

Oxytocin

Clinical Study ID

NCT05627791
65065
  • Ages 50-70
  • Female
  • Accepts Healthy Volunteers

Study Summary

Vulvovaginal atrophy affects around 90% of postmenopausal women who may present with symptoms such as dryness, irritation, itching, burning, and dyspareunia that negatively affect the quality of life. Topical estrogen is recommended for the treatment of vulvovaginal atrophy in postmenopausal women and the FDA approved it. But it may increase the risk of breast and endometrial cancer. The oxytocin hormone also promotes positive social behavior, stress regulation, and female sexual arousal. Many previous studies show that topical oxytocin is useful for reducing vaginal atrophy in postmenopausal women.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Thai menopausal women aged between 50-70 years who visit Rajavithi gynecology OPD withinformed consent with good communication in the Thai language.

Exclusion

Exclusion Criteria:

  • Have acute vulvovaginitis (vaginal swab for wet smear and KOH)
  • Patients who have used hormonal replacement therapy within 12 months
  • Patients with a history of smoking
  • Patients who have used vaginal lubricant or moisturizer
  • Patients with an allergic history of oxytocin or gel components
  • Morbid obesity BMI > 30 kg/m2
  • Patients who have used vitamin E supplement
  • Patients who unable to perform per vaginal examination

Study Design

Total Participants: 6
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2/3
Study Start date:
November 30, 2022
Estimated Completion Date:
August 28, 2023

Study Description

Random and conducted on 56 postmenopausal women who meet the inclusion criteria and excluded participants that have exclusion criteria. All women provided written informed consent before data collection.

  1. st Visit: The vagina was assessed regarding infection and any abnormal discharge. The participants were evaluated vaginal signs of vaginal atrophy by per vaginal examination and assessed vaginal health index score. The subjective symptoms were assessed by The most bothersome score. The vaginal pH was tested with a Nitrazine paper. The vaginal swab was done and the specimen was sent for a cytological test - vaginal maturation index evaluation (VMI). The participants were separated into two groups 1. Oxytocin gel group and 2. Placebo gel group then applied gel 1 ml. (400IU of oxytocin in oxytocin gel) per day for 8 weeks consecutively. The subjective symptoms were assessed at 2 and 4 weeks by phone.

  2. nd Visit: The participants were assessed the same as 1st visit that recorded vaginal health index score, subjective symptoms, vaginal pH, and vaginal maturation index evaluation.

Connect with a study center

  • Rajavithi Hospital

    Bangkok, 10400
    Thailand

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.